Introduction {#Sec1}
============

The economic and clinical burden of diabetes in Slovakia is ever-increasing, with 7--10% of the population diagnosed with diabetes in 2017 and direct healthcare expenditure exceeding EUR 650 million \[[@CR1]--[@CR3]\]. This is expected to rise to over EUR 730 million by 2040, with the costs of treating diabetes-related complications representing the biggest proportion of overall expenditure \[[@CR1], [@CR4]\]. Therefore, choosing cost-effective therapies that reduce the incidence of long-term complications, offering improvements in health outcomes for patients while managing costs for the healthcare payer, is imperative.

Treatments for type 2 diabetes typically focus on reducing glycated hemoglobin (HbA1c) levels, as glycemic control has been shown to reduce the incidence of diabetes-related complications in the long term \[[@CR5]--[@CR9]\]. More recently, reductions in additional risk factors, such as body weight and systolic blood pressure, have been shown to provide further benefits \[[@CR10]--[@CR13]\]. In Slovakia, 64% of patients with type 2 diabetes were estimated to be overweight and 27% were estimated to be obese, while the risk of mortality from cardiovascular complications is two- to three-fold higher in patients with type 2 diabetes versus people with no history of the disease \[[@CR3], [@CR14], [@CR15]\]. Even modest reductions in HbA1c and body weight have been associated with lowered cardiovascular disease risk, with a 1% reduction in HbA1c linked with risk reductions of 16%, 4% and 12% for heart failure, myocardial infarction and stroke, respectively, while weight loss of between 5% and 10% has been associated with statistically significant improvements in risk factors for cardiovascular disease \[[@CR16], [@CR17]\]. Therapies that target multiple risk factors are therefore becoming increasingly utilized throughout the type 2 diabetes treatment algorithm \[[@CR18]\].

Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists has been associated with multifactorial benefits, such as reductions in body weight and systolic blood pressure, in addition to improved glycemic control \[[@CR19]--[@CR22]\]. Among GLP-1 receptor agonists, the short-term efficacy of once-weekly semaglutide, in terms of greater reductions in HbA1c and body weight, has been demonstrated versus a variety of comparators throughout the SUSTAIN clinical trial program and several network meta-analyses (NMAs) \[[@CR23]--[@CR28]\]. Once-weekly semaglutide has also been associated with statistically significant reductions in the risk of major adverse cardiovascular events (MACE) versus placebo in SUSTAIN 6, akin to results seen for liraglutide in LEADER \[[@CR29], [@CR30]\]. However, it is unclear whether these benefits are innate to GLP-1 receptor agonists as a class, as exenatide extended-release (ER) and lixisenatide did not display benefits compared with placebo in EXSCEL and ELIXA, respectively \[[@CR31], [@CR32]\]. Preliminary reports from REWIND indicate that dulaglutide is associated with superior reductions in the risk of MACE versus placebo, but the extent of these reductions is unclear, with a full publication currently pending \[[@CR33]\].

Guidelines for the treatment of type 2 diabetes in Slovakia follow international consensus statements published by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), which advise GLP-1 receptor agonists as the first-line injectable therapy, particularly following metformin failure in patients with a high risk of cardiovascular disease or seeking to minimize weight gain or achieve weight loss \[[@CR18]\]. In the latter case, once-weekly semaglutide is indicated as the preferred treatment option with the best efficacy for weight loss \[[@CR18]\].

In Slovakia, healthcare coverage is universal through compulsory insurance, with care provided free of charge to insured individuals at the point of delivery \[[@CR34]\]. In this system, the only currently available once-weekly GLP-1 receptor agonist is dulaglutide 1.5 mg, which is reimbursed in patients with a body mass index (BMI) \> 35 kg/m^2^. Both doses of once-weekly semaglutide have shown short-term benefits versus dulaglutide in the SUSTAIN 7 clinical trial \[[@CR26]\]. The present analysis aimed to examine the impact of these benefits on long-term clinical and cost outcomes and thereby evaluate the long-term cost-effectiveness of once-weekly semaglutide 0.5 mg and 1 mg versus dulaglutide 1.5 mg in patients with inadequate glycemic control on metformin with a BMI \> 35 kg/m^2^ in Slovakia.

Methods {#Sec2}
=======

Model Overview {#Sec3}
--------------

Cost-effectiveness was estimated using the IQVIA CORE Diabetes Model, a web-based computer model that simulates the long-term health and economic outcomes of interventions for the treatment of type 1 and type 2 diabetes \[[@CR35], [@CR36]\]. Model outcomes include direct medical costs, life expectancy (measured in years), quality-adjusted life expectancy \[measured in quality-adjusted life years (QALYs)\], the cumulative incidence and time to onset of diabetes-related complications and cost-effectiveness scatterplots and acceptability curves. In cases where an intervention is associated with increased costs and greater clinical benefits, costs and effectiveness are combined to give an incremental cost-effectiveness ratio (ICER), describing the incremental cost per unit of effectiveness gained for the tested intervention versus the comparator. In scenarios where an intervention is associated with reduced costs and increased clinical benefits, it is considered dominant versus the comparator. The model has been validated versus real-life data at both the time of release in 2004 and more recently in 2014 and is frequently used and widely accepted by health technology assessment bodies globally \[[@CR36], [@CR37]\].

Analyses were performed over patient lifetimes, as per the guidelines for the assessment of cost-effectiveness of diabetes interventions, capturing all relevant long-term complications experienced by patients and the associated treatment costs \[[@CR38]\]. All analyses utilized Slovakia-specific life tables for background mortality, with remaining mortality considered as a result of diabetes-related complications \[[@CR39]\]. The risk of cardiovascular complications was predicted using the UKPDS 68 equations \[[@CR40]\]. All base case and sensitivity analyses took a first-order Monte Carlo approach, while a second-order Monte Carlo approach was used for the probabilistic sensitivity analysis (PSA). Discounting for clinical and cost outcomes was set at 5.0% annually, in line with guidelines for health economic analyses in Slovakia \[[@CR41]\].

Clinical Data {#Sec4}
-------------

Baseline cohort characteristics were based on the sub-group of patients with a BMI \> 35 kg/m^2^, extracted post-hoc from the SUSTAIN 7 clinical trial (Table [1](#Tab1){ref-type="table"}). The number of cigarettes smoked per day and mean weekly alcohol consumption were unavailable from the trial data, and these were therefore based on Slovakia-specific data for the general population \[[@CR42], [@CR43]\].Table 1Baseline cohort characteristics of patients with a BMI \> 35 kg/m^2^ in SUSTAIN 7CharacteristicMean (standard deviation)Start age (years)53.94 (10.10)Duration of diabetes (years)7.05 (5.34)^a^Percentage male (%)48.28HbA1c (%)8.23 (0.92)Systolic blood pressure (mmHg)134.83 (13.79)Diastolic blood pressure (mmHg)82.54 (9.32)Total cholesterol (mg/dl)180.00 (41.71)HDL cholesterol (mg/dl)43.84 (10.51)LDL cholesterol (mg/dl)99.96 (35.69)Triglycerides (mg/dl)191.82 (109.02)BMI (kg/m^2^)40.49 (5.26)Percentage smokers (%)15.33Cigarettes per day14.70^b^Alcohol consumption (oz/week)6.87^c^All data were taken from SUSTAIN 7, unless otherwise indicated*BMI* body mass index, *HbA1c* glycated hemoglobin, *HDL* high-density lipoprotein, *LDL* low-density lipoprotein^a^Rounded to 7.00 in the analysis, as the model only accepts integer values for duration of diabetes^b^Based on data published by the Statistical Office of the Slovak Republic \[[@CR42]\]^c^Based on data published by the World Health Organization \[[@CR43]\]

Treatment effects relating to physiological parameters were also based on the sub-group of patients with a BMI \> 35 kg/m^2^ in SUSTAIN 7 (Table [2](#Tab2){ref-type="table"}). While pre-specified analyses assessed the statistical significance of treatment effect differences between once-weekly semaglutide 1 mg and dulaglutide 1.5 mg, post-hoc analyses were required to assess the statistical significance of treatment effect differences between once-weekly semaglutide 0.5 mg and dulaglutide 1.5 mg. These showed that once-weekly semaglutide 0.5 mg was associated with non-statistically significant reductions in HbA1c, cholesterol and BMI, while once-weekly semaglutide 1 mg was associated with statistically significant reductions in HbA1c and BMI and non-statistically significant reductions in diastolic blood pressure and cholesterol compared with dulaglutide 1.5 mg. Both statistically significant and non-statistically significant differences were applied, in line with modeling guidelines \[[@CR44]\].Table 2Treatment effects and adverse event rates included in the analysisParameterMean (standard error)Once-weekly semaglutide 0.5 mgOnce-weekly semaglutide 1 mgDulaglutide 1.5 mgPhysiological parameters (applied in the first year of the analysis) HbA1c (%)− 1.52 (0.08)− 1.72 (0.09)\*− 1.36 (0.09) Systolic blood pressure (mmHg)− 2.82 (1.13)− 3.93 (1.18)− 4.19 (1.16) Diastolic blood pressure (mmHg)− 0.83 (0.69)− 2.03 (0.71)− 1.04 (0.70) Total cholesterol (mg/dl)− 8.24 (2.43)− 4.59 (2.52)− 1.45 (2.48) HDL cholesterol (mg/dl)− 1.19 (0.46)0.35 (0.47)0.80 (0.46) LDL cholesterol (mg/dl)− 3.49 (2.07)− 0.74 (2.14)2.17 (2.11) Triglycerides (mg/dl)− 23.71 (5.72)− 24.66 (5.90)− 25.54 (5.82) BMI (kg/m^2^)− 1.95 (0.17)− 2.73 (0.18)\*− 1.32 (0.18) Estimated glomerular filtration rate (ml/min/1.73 m^2^)− 2.71 (0.83)− 3.15 (0.88)− 3.39 (0.83)Adverse event rates (applied in the first 3 years of the analysis) Non-severe hypoglycemia events, per 100 patient years3.372.491.13 Severe hypoglycemia events, per 100 patient years0.001.241.13 Proportion of non-severe hypoglycemic events that are nocturnal0.000.000.00 Proportion of severe hypoglycemic events that are nocturnal0.000.000.00*BMI* body mass index, *HbA1c* glycated hemoglobin, *HDL* high-density lipoprotein, *LDL* low-density lipoprotein\*Statistically significant difference at 95% confidence level versus dulaglutide 1.5 mg

Treatment Duration, Intensification and Long-Term Parameter Progression {#Sec5}
-----------------------------------------------------------------------

Patients were modeled to receive once-weekly semaglutide or dulaglutide for the first 3 years of the analysis, based on a 2017 review of the current treatment landscape of type 2 diabetes, which reported that the average duration of GLP-1 receptor agonist treatment was 29.4 months \[[@CR45]\]. As treatment switching is only possible at the end of a given year in the IQVIA CORE Diabetes Model, this was rounded up to 3 years. This approach is in line with previous long-term cost-effectiveness analyses of GLP-1 receptor agonists submitted to the Scottish Medicines Agency (SMC) and the National Institute for Health and Care Excellence (NICE) and published in peer reviewed journals \[[@CR46]--[@CR51]\]. After 3 years, once-weekly semaglutide or dulaglutide treatment was discontinued, with patients intensifying to insulin glargine U100 (Abasaglar^®^). This assumption recognizes the progressive nature of type 2 diabetes, with intensification to basal insulin therapy often needed for patients to maintain glycemic control in the long term.

Benefits in HbA1c and BMI with once-weekly semaglutide and dulaglutide were maintained during the 3 years patients received these treatments. Following intensification to basal insulin, HbA1c was brought to 7.0% in all treatment arms, as the baseline cohort characteristics justified an HbA1c target of 7.0%, according to ADA and EASD guidelines for glycemic targets in patients with type 2 diabetes (which recommend individualizing HbA1c targets based on patient factors), while BMI reverted to baseline for the remainder of patient lifetimes \[[@CR52]\]. This resulted in a balanced cost-effectiveness analysis, with differences in HbA1c and BMI maintained only while there were differences in costs. Changes in blood pressure and serum lipids were assumed to follow the natural progression algorithms built into the IQVIA CORE Diabetes Model in all arms, based on the UKPDS or Framingham data (as described by Palmer et al.) \[[@CR35]\]. Sensitivity analyses were conducted to explore alternate treatment switching approaches and parameter progression assumptions.

Costs, Resource Use and Utilities {#Sec6}
---------------------------------

Costs were accounted from a Slovakian healthcare payer perspective and expressed in euros (EUR). Unit costs of diabetes medications and consumables were based on retail prices in Slovakia, with calculations reflecting the maximum reimbursement levels for needles and self-monitoring of blood glucose (SMBG) testing equipment for patients receiving basal insulin therapy, following treatment intensification.

Diabetes medication resource use was based on the sub-group of patients with a BMI \> 35 kg/m^2^ in the SUSTAIN 7 trial, including the ubiquitous use of concomitant metformin, which was priced according to a weighted average of metformin products used in Slovakia. No SMBG use was associated with once-weekly semaglutide or dulaglutide treatment. No needles were required for administration, as they are included in the once-weekly semaglutide and dulaglutide packs.

Following intensification after 3 years, patients were assumed to receive 40 IU insulin glargine U100 (Abasaglar), based on the defined daily dose (DDD), with universal concomitant metformin use continuing in all treatment arms. Patients were assumed to use the maximum number of reimbursable needles (200) and SMBG test strips (300) and lancets (100) annually. The impact of the cost of consumables was assessed in the sensitivity analyses, which removed consumables use for all treatment arms. Resource use was used to calculate annual treatment costs (Table [3](#Tab3){ref-type="table"}).Table 3Annual costs in the base case analysisItemOnce-weekly semaglutide 0.5 mgOnce-weekly semaglutide 1 mgDulaglutide 1.5 mgBasal insulin (intensification)Annual medication cost1237.941237.941237.94411.90Annual metformin cost39.8139.8139.8139.81Annual needle cost0.000.000.0026.30Annual SMBG testing cost0.000.000.0077.98Total annual cost1277.751277.751277.75556.00All costs expressed in euros (EUR). The medication cost of Abasaglar was used for basal insulin*SMBG* self-monitoring of blood glucose

Slovakia-specific costs of treating diabetes-related complications, in both the year of onset and annual follow-up costs, were identified from a published source \[[@CR53]\]. Utilities relating to quality of life were taken from a 2014 review by Beaudet et al., with the exception of hypoglycemic event disutilities, which were sourced from a 2013 publication by Evans et al. (published after the literature searches by Beaudet et al. had been conducted) \[[@CR54], [@CR55]\].

Sensitivity Analyses {#Sec7}
--------------------

Sensitivity analyses were conducted to test the robustness of the base case results, thereby examining the uncertainty associated with long-term extrapolation of clinical and cost outcomes from short-term data. An analysis was performed with only statistically significant differences between the treatment arms applied. The impact of shortening the time horizon was examined by conducting analyses with 10- and 20-year time horizons applied, for which it should be noted that not all diabetes-related complications and associated costs were captured, as the duration of the analyses was not sufficient for all patients to have died. The influence of discounting on cost and clinical outcomes was assessed by applying discount rates of 0% and 10% in separate simulations. The impact of differences in HbA1c on overall outcomes was evaluated in an analysis with only the difference in HbA1c between the treatment arms applied in the once-weekly semaglutide arms, with all other parameters equal to the dulaglutide arm.

Alternative HbA1c and BMI progressions were explored in separate analyses, with one applying the UKPDS progression equation for HbA1c in all treatment arms, with differences between the treatment arms gradually abolished, and the other assuming BMI differences between the treatment arms were maintained for patient lifetimes. Variations in treatment effects were assessed in separate analyses through application of the upper and lower limits of the 95% confidence intervals of the estimated treatment differences in HbA1c and BMI.

Alternative treatment switching approaches were evaluated by bringing forward treatment switching to the end of year 2 and pushing treatment switching back to the end of year 5 in all arms, as well as HbA1c progression following the UKPDS equations and treatment switching occurring when HbA1c exceeded 7.5%. The impact of over- or underestimating the costs of complications was assessed by increasing and decreasing these costs by 10% in separate analyses, while the influence of the costs of consumables (needles and SMBG testing) was tested by performing simulations with these costs excluded. Separate analyses were also conducted with alternative BMI and hypoglycemia disutilities applied, which gave greater impact to weight changes and non-severe hypoglycemic events, respectively \[[@CR56], [@CR57]\]. An additional analysis was performed with a diminishing hypoglycemia disutility model applied \[[@CR58]\].

PSA, which captured statistical uncertainty by sampling around parameter inputs, was conducted with a second-order Monte Carlo approach using the predefined function in the IQVIA CORE Diabetes Model. Sampling was applied to baseline characteristics, treatment effects, event risks, costs and utilities.

Compliance with Ethics Guidelines {#Sec8}
---------------------------------

This article does not contain any studies with human participants or animals performed by any of the authors.

Results {#Sec9}
=======

Base Case Analysis {#Sec10}
------------------

Projections of long-term clinical outcomes in patients with a BMI \> 35 kg/m^2^ with inadequate glycemic control on OADs indicated that once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in discounted life expectancy of 0.04 and 0.06 years, respectively, and discounted quality-adjusted life expectancy of 0.04 and 0.07 QALYs, respectively, versus dulaglutide 1.5 mg (Table [4](#Tab4){ref-type="table"}). Clinical benefits resulted from a reduced incidence and delayed time to onset of diabetes-related complications in the once-weekly semaglutide arms over the 50-year time horizon of the analysis. Benefits were observed across all included micro- and macrovascular complications (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Mean time to onset of diabetes-related complicationsTable 4Long-term cost-effectiveness outcomes in the base case analysisHealth outcomesOnce-weekly semaglutide 0.5 mgDulaglutide 1.5 mgDifferenceDiscounted life expectancy (years)11.61 (0.15)11.57 (0.15)+ 0.04Discounted quality-adjusted life expectancy (QALYs)7.19 (0.09)7.16 (0.10)+ 0.04Discounted direct costs (EUR)18,686 (399)18,706 (404)− 20ICER based on life expectancy and direct costsOnce-weekly semaglutide 0.5 mg dominantICER based on quality-adjusted life expectancy and direct costsOnce-weekly semaglutide 0.5 mg dominantHealth outcomesOnce-weekly semaglutide 1 mgDulaglutide 1.5 mgDifferenceDiscounted life expectancy (years)11.63 (0.15)11.57 (0.15)+ 0.06Discounted quality-adjusted life expectancy (QALYs)7.23 (0.10)7.16 (0.10)+ 0.07Discounted direct costs (EUR)18,566 (402)18,706 (404)− 140ICER based on life expectancy and direct costsOnce-weekly semaglutide 1 mg dominantICER based on quality-adjusted life expectancy and direct costsOnce-weekly semaglutide 1 mg dominantValues are means (standard deviations)*EUR* euros, *ICER* incremental cost-effectiveness ratio, *QALYs* quality-adjusted life years

Long-term projections of direct medical costs suggested that the mean lifetime cost per patient was EUR 20 lower with once-weekly semaglutide 0.5 mg and EUR 140 lower with once-weekly semaglutide 1 mg versus dulaglutide 1.5 mg (Fig. [2](#Fig2){ref-type="fig"}). Treatment costs were EUR 20 and EUR 31 higher with once-weekly semaglutide 0.5 mg and 1 mg, respectively, versus dulaglutide 1.5 mg, as, despite equivalent unit costs, the increased survival and further treatment of patients over the long term led to increased expenditure. This was entirely offset by cost savings due to avoidance of diabetes-related complications, most notably ulcer, amputation and neuropathy complications and fewer severe hypoglycemic events with once-weekly semaglutide 0.5 mg (both yielding mean cost savings of EUR 16 per patient) and cardiovascular complications with once-weekly semaglutide 1 mg (yielding mean cost savings of EUR 128 per patient).Fig. 2Direct costs over patient lifetimes. EUR, euros

With both improved life expectancy and quality-adjusted life expectancy, achieved at a reduced cost from a healthcare payer perspective, once-weekly semaglutide 0.5 mg and 1 mg were considered dominant versus dulaglutide 1.5 mg.

One- and Multi-Way Sensitivity Analyses {#Sec11}
---------------------------------------

Sensitivity analyses, conducted around model inputs and assumptions, showed that the base case findings were robust to changes in these parameters, with once-weekly semaglutide 0.5 mg and 1 mg remaining dominant versus dulaglutide 1.5 mg in the majority of scenarios (Table [5](#Tab5){ref-type="table"}). Application of only statistically significant differences between the treatment arms led to no differences between the once-weekly semaglutide 0.5 mg and dulaglutide 1.5 mg arms, as all differences in treatment effects between these arms observed in SUSTAIN 7 were not significant, while once-weekly semaglutide 1 mg was associated with comparable clinical benefits and cost savings to the base case analysis and remained dominant. Application of 10- and 20-year time horizons reduced the clinical benefits associated with once-weekly semaglutide treatment, but both doses remained dominant versus dulaglutide 1.5 mg. These outcomes demonstrate how once-weekly semaglutide is associated with long-term benefits, not all of which are captured with shorter time horizons. Altering the discount rate also reflected this, with clinical benefits for both doses of once-weekly semaglutide greatly increased with discount rates of 0% applied. Once-weekly semaglutide 1 mg remained cost saving and dominant, but once-weekly semaglutide 0.5 mg was associated with small cost increases, yielding an ICER of EUR 160 per QALY gained. Applying discount rates of 10% decreased the clinical benefits associated with once-weekly semaglutide 0.5 mg and 1 mg, but both remained cost saving and dominant versus dulaglutide 1.5 mg.Table 5Sensitivity analysis resultsAnalysisOnce-weekly semaglutide 0.5 mg versus dulaglutide 1.5 mgOnce-weekly semaglutide 1 mg versus dulaglutide 1.5 mgDifference in discounted quality-adjusted life expectancy (QALYs)Difference in discounted direct costs (EUR)ICER (EUR per QALY gained)Difference in discounted quality-adjusted life expectancy (QALYs)Difference in discounted direct costs (EUR)ICER (EUR per QALY gained)Base case+ 0.04− 20Once-weekly semaglutide dominant+ 0.07− 140Once-weekly semaglutide dominantStatistically significant differences only0.000Once-weekly semaglutide equally effective and equally costly+ 0.07− 99Once-weekly semaglutide dominant20-year time horizon+ 0.01− 21Once-weekly semaglutide dominant+ 0.04− 105Once-weekly semaglutide dominant10-year time horizon+ 0.02− 36Once-weekly semaglutide dominant+ 0.04− 53Once-weekly semaglutide dominant0% discount rates+ 0.08+ 13160+ 0.14− 240Once-weekly semaglutide dominant5% discount rates+ 0.02− 26Once-weekly semaglutide dominant+ 0.05− 93Once-weekly semaglutide dominantHbA1c difference only+ 0.02− 61Once-weekly semaglutide dominant+ 0.03− 130Once-weekly semaglutide dominantBMI difference maintained for patient lifetimes+ 0.07− 20Once-weekly semaglutide dominant+ 0.15− 138Once-weekly semaglutide dominantUKPDS HbA1c creep for duration of the analysis (no change upon treatment intensification)+ 0.02− 107Once-weekly semaglutide dominant+ 0.06− 116Once-weekly semaglutide dominantUpper 95% CI of HbA1c estimated treatment difference+ 0.04− 113Once-weekly semaglutide dominant+ 0.09-- 140Once-weekly semaglutide dominantLower 95% CI of HbA1c estimated treatment difference+ 0.02− 56Once-weekly semaglutide dominant+ 0.06− 82Once-weekly semaglutide dominantUpper 95% CI of BMI estimated treatment difference+ 0.05− 74Once-weekly semaglutide dominant+ 0.08− 133Once-weekly semaglutide dominantLower 95% CI of BMI estimated treatment difference+ 0.02− 35Once-weekly semaglutide dominant+ 0.06− 143Once-weekly semaglutide dominantTreatment switching at 2 years+ 0.03− 72Once-weekly semaglutide dominant+ 0.06− 64Once-weekly semaglutide dominantTreatment switching at 5 years+ 0.02− 71Once-weekly semaglutide dominant+ 0.07− 111Once-weekly semaglutide dominantTreatment switching at 7.5% HbA1c threshold (using UKPDS progression)+ 0.02− 157Once-weekly semaglutide dominant+ 0.10+ 3123137Cost of complications + 10%+ 0.04− 24Once-weekly semaglutide dominant+ 0.07− 158Once-weekly semaglutide dominantCost of complications − 10%+ 0.04− 16Once-weekly semaglutide dominant+ 0.07− 123Once-weekly semaglutide dominantCost of consumables excluded+ 0.04− 24Once-weekly semaglutide dominant+ 0.07− 146Once-weekly semaglutide dominantLee et al. BMI disutility applied+ 0.03− 20Once-weekly semaglutide dominant+ 0.08− 140Once-weekly semaglutide dominantDiminishing hypoglycemia disutility applied+ 0.04− 20Once-weekly semaglutide dominant+ 0.07− 140Once-weekly semaglutide dominantCurrie et al. hypoglycemia disutility applied+ 0.04− 20Once-weekly semaglutide dominant+ 0.07− 140Once-weekly semaglutide dominant*BMI* body mass index, *CI* confidence interval, *EUR* euros, *HbA1c* glycated hemoglobin, *ICER* incremental cost-effectiveness ratio, *QALY* quality-adjusted life year

Analyses conducted with only the treatment differences in HbA1c applied showed that these reductions were a substantial contributor to overall clinical outcomes, with both doses of once-weekly semaglutide remaining dominant versus dulaglutide 1.5 mg. Maintaining the BMI differences after treatment intensification to cover patient lifetimes resulted in increased incremental clinical benefits with once-weekly semaglutide, with incremental costs remaining similar to the base case analysis. Modeling HbA1c using the UKPDS progression equation following application of treatment effects in the first year of the analysis led to decreased quality-adjusted life expectancy in all treatment arms, but both doses of once-weekly semaglutide remained dominant.

Applying the upper limit of the 95% confidence interval of the estimated treatment differences in HbA1c resulted in maintained incremental benefits from the base case for once-weekly semaglutide 0.5 mg and increased incremental benefits for once-weekly semaglutide 1 mg, while use of the lower limit led to decreased clinical benefits for both doses. Application of the upper limit for differences in BMI resulted in increased incremental benefits for both once-weekly semaglutide 0.5 mg and 1 mg, while use of the lower limit had the opposite effect, with benefits reduced.

Bringing treatment switching forward to the end of year 2 resulted in reduced clinical benefits for once-weekly semaglutide 0.5 mg and 1 mg, but both remained dominant versus dulaglutide 1.5 mg. Pushing treatment switching back to the end of year 5 led to reduced incremental clinical benefits for once-weekly semaglutide 0.5 mg but increased clinical benefits for once-weekly semaglutide 1 mg, and both remained cost saving and dominant versus dulaglutide 1.5 mg. Applying the UKPDS progression equation and having treatment switching occur when HbA1c exceeded 7.5% resulted in reduced clinical benefits but increased cost savings for once-weekly semaglutide 0.5 mg and greater clinical benefits but increased incremental costs for once-weekly semaglutide 1 mg, yielding an ICER of EUR 3137 per QALY gained.

Increasing and decreasing the costs of complications by 10% resulted in only minor changes to incremental cost outcomes, and both doses of once-weekly semaglutide remained dominant. Similarly, excluding the costs of complications did not drastically alter cost outcomes, and once-weekly semaglutide 0.5 mg and 1 mg remained dominant versus dulaglutide 1.5 mg. Use of alternative disutilities for BMI and hypoglycemia resulted in only minor changes to clinical outcomes, and both doses of once-weekly semaglutide remained dominant versus dulaglutide 1.5 mg.

Probabilistic Sensitivity Analysis {#Sec12}
----------------------------------

PSA, performed with sampling around cohort characteristics, treatment effects, complication costs and utilities, displayed comparable mean outcomes to the base case analysis, but yielded increased measures of variance around the mean results (Fig. [3](#Fig3){ref-type="fig"}). The mean incremental improvements in quality-adjusted life expectancy with once-weekly semaglutide 0.5 mg and 1 mg were 0.02 and 0.07 QALYs, respectively, versus dulaglutide 1.5 mg. Mean costs were estimated to be EUR 9 higher with once-weekly semaglutide 0.5 mg and EUR 93 lower with once-weekly semaglutide 1 mg versus dulaglutide 1.5 mg. Therefore, once-weekly semaglutide 0.5 mg was associated with an ICER of EUR 401 per QALY gained, while once-weekly semaglutide 1 mg was considered dominant versus dulaglutide 1.5 mg in the PSA. Based on a willingness-to-pay threshold of EUR 25,536 per QALY gained (the lowest possible threshold for an intervention in 2018, 28 times the average monthly wage in Slovakia), the modeling analysis indicated that the probabilities of once-weekly semaglutide 0.5 mg and 1 mg being cost-effective were 57.1% and 72.4%, respectively, versus dulaglutide 1.5 mg.Fig. 3Probabilistic sensitivity analysis scatterplot. EUR, euros; QALY, quality-adjusted life year. Based on a willingness-to-pay threshold of EUR 25,536 per QALY gained (the lowest possible threshold for an intervention in 2018, 28 times the average monthly wage in Slovakia), the modeling analysis indicated that the probabilities of once-weekly semaglutide 0.5 mg and 1 mg being cost-effective were 57.1% and 72.4%, respectively, versus dulaglutide 1.5 mg

Discussion {#Sec13}
==========

The present analysis indicated that once-weekly semaglutide 0.5 mg and 1 mg are dominant treatment options versus dulaglutide 1.5 mg for the treatment of patients with type 2 diabetes with inadequate glycemic control on metformin and with a BMI \> 35 kg/m^2^ in Slovakia. Clinical outcomes of life expectancy and quality-adjusted life expectancy were improved with once-weekly semaglutide treatment, with a delayed time to onset and reduced cumulative incidence of diabetes-related complications leading to lifetime cost savings compared with dulaglutide 1.5 mg from a healthcare payer perspective.

Treatment guidelines for type 2 diabetes in Slovakia follow international recommendations published by the ADA and EASD \[[@CR18]\]. These position GLP-1 receptor agonists as a second-line therapy (alongside sodium-glucose cotransporter-2 \[SGLT-2\] inhibitors) in patients with inadequate glycemic control on metformin, particularly for patient groups with high cardiovascular disease risk or those looking to avoid weight gain. The use of data from a head-to-head trial, with a patient population with inadequate glycemic control on metformin and a BMI \> 35 kg/m^2^, represents a key strength of the present analysis. Additionally, in Slovakia, dulaglutide is currently reimbursed only in patients with a BMI \> 35 kg/m^2^, and so the choice of this sub-group from SUSTAIN 7 provides pertinent information for a Slovakian healthcare payer considering alternative GLP-1 receptor agonist therapies. The clinical benefits observed with once-weekly semaglutide in this patient sub-group are also seen in the full population of SUSTAIN 7, and once-weekly semaglutide remains consistently efficacious across sub-groups versus numerous comparators throughout the SUSTAIN trial program \[[@CR59]--[@CR61]\]. Long-term analyses conducted in the UK and Canada have shown that these short-term benefits in the full population of SUSTAIN 7 translate to further benefits over patient lifetimes \[[@CR51], [@CR62]\]. Once-weekly semaglutide is therefore likely to remain a cost-effective treatment option versus dulaglutide in Slovakia if weight restrictions are removed from the reimbursement criteria.

An aspect of treatment that could not be incorporated into the present analysis was the cardiovascular benefits offered by GLP-1 receptor agonists, as health economic models for diabetes are yet to incorporate risk equations based on cardiovascular outcome studies. Once-weekly semaglutide has been associated with statistically significant reductions in the risk of MACE versus placebo in SUSTAIN 6, while preliminary results from REWIND suggest dulaglutide is also associated with superiority, although the extent of these improvements are yet to be fully disseminated \[[@CR29], [@CR33]\]. GLP-1 analog liraglutide has also been associated with improved cardiovascular outcomes versus placebo in LEADER, but exenatide ER and lixisenatide did not display benefits compared with placebo in EXSCEL and ELIXA, respectively, indicating that cardiovascular benefits are not innate across the GLP-1 receptor agonist class and are instead specific to certain medications \[[@CR30]--[@CR32]\]. Further studies are needed to elucidate differences in cardiovascular outcomes between GLP-1 receptor agonist therapies. However, given the benefits in other aspects of treatment once-weekly semaglutide offers, the current evidence supports reimbursement of once-weekly semaglutide in Slovakia.

A limitation of the study, inherent to all long-term health economic analyses, was the projection of long-term outcomes from relatively short-term clinical trial data. However, in the absence of long-term data, this method represents the best available option for evaluating diabetes medications, and projecting outcomes over patient lifetimes is recommended in the guidelines for assessing the cost-effectiveness of diabetes interventions \[[@CR38]\]. The use of a published and extensively validated model, as well as numerous sensitivity analyses that test the assumptions and data inputs used, also gives weight to the results and supports the conclusion that once-weekly semaglutide is cost-effective versus dulaglutide 1.5 mg \[[@CR36], [@CR37]\].

Conclusions {#Sec14}
===========

Once-weekly semaglutide 0.5 mg and 1 mg represent cost-saving treatment options versus dulaglutide 1.5 mg for the treatment of patients with type 2 diabetes with inadequate glycemic control on metformin and a BMI \> 35 kg/m^2^ in Slovakia.
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